By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protein diagnostic firm Courtagen said today that it has entered into a collaboration with Avaxia Biologics to create an assay for use in developing an oral antibody therapy to mitigate the gastrointestinal damage caused by radiation exposure.

The therapy being developed is for use in radiation exposure from a nuclear incident.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.